A Her2-let-7-β2-AR circuit affects prognosis in patients with Her2-positive breast cancer

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Liu, Dan ^a   Deng, Que ^a   Sun, Limin ^a   Wang, Tao ^b   Yang, Zhengyan ^a   Chen, Hongyu ^a   Guo, Liang ^a   Liu, Yanjun ^c   Ma, Yuanfang ^c   Guo, Ning ^a   Shi, Ming ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b Beijing 307 Hospital   (China)

^c HENAN UNIVERSITY   (China)

Author keywords

Breast cancer; Her2; Let 7f; Prognosis; 2 AR

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; BETA 2 ADRENERGIC RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ISOPRENALINE; MICRORNA; MICRORNA LET 7F; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; MIRNLET7 MICRORNA, HUMAN;

ARTICLE; BREAST CANCER; CANCER TISSUE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENETIC TRANSFECTION; HER2 POSITIVE BREAST CANCER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MCF 7 CELL LINE; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF-7 CELL LINE; PATHOLOGY; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICRORNAS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION;

EID: 84945976473     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1869-6     Document Type: Article

References (35)

1. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25(3):282-303.
2. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9(7):463-75.
3. Shi M, Liu D, Duan H, Qian L, Wang L, Niu L, et al. The beta2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells. Breast Cancer Res Treat. 2011;125(2):351-62.
4. Shi M, Yang Z, Hu M, Liu D, Hu Y, Qian L, et al. Catecholamine-Induced beta2-adrenergic receptor activation mediates desensitization of gastric cancer cells to trastuzumab by upregulating MUC4 expression. J Immunol. 2013;190(11):5600-8.
5. Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res. 2012;18(5):1201-6.
6. Shi M, Liu D, Yang Z, Guo N. Central and peripheral nervous systems: master controllers in cancer metastasis. Cancer Metastasis Rev. 2013;32(3-4):603-21.
7. Shi M, Liu D, Duan H, Han C, Wei B, Qian L, et al. Catecholamine up-regulates MMP-7 expression by activating AP-1 and STAT3 in gastric cancer. Mol Cancer. 2010;9:269.
8. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12(8):939-44.
9. Powe DG, Voss MJ, Habashy HO, Zanker KS, Green AR, Ellis IO, et al. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study. Breast Cancer Res Treat. 2011;130(2):457-63.
10. Hassan S, Karpova Y, Baiz D, Yancey D, Pullikuth A, Flores A, et al. Behavioral stress accelerates prostate cancer development in mice. J Clin Invest. 2013;123(2):874-86.
11. Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ, et al. Autonomic nerve development contributes to prostate cancer progression. Science. 2013;341(6142):1236361.
12. Wang WC, Juan AH, Panebra A, Liggett SB. MicroRNA let-7 establishes expression of beta2-adrenergic receptors and dynamically down-regulates agonist-promoted down-regulation. Proc Natl Acad Sci U S A. 2011;108(15):6246-51.
13. Barh D, Malhotra R, Ravi B, Sindhurani P. MicroRNA let-7: an emerging next-generation cancer therapeutic. Curr Oncol. 2010;17(1):70-80.
14. Paroo Z, Ye X, Chen S, Liu Q. Phosphorylation of the human microRNA-generating complex mediates MAPK/Erk signaling. Cell. 2009;139(1):112-22.
15. Yuan G, Qian L, Shi M, Lu F, Li D, Hu M, et al. HER2-dependent MMP-7 expression is mediated by activated STAT3. Cell Signal. 2008;20(7):1284-91.
16. Wang Y, Hu X, Greshock J, Shen L, Yang X, Shao Z, et al. Genomic DNA copy-number alterations of the let-7 family in human cancers. PLoS One. 2012;7(9):e44399.
17. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006;5:24.
18. Shi M, Zhao M, Hu M, Liu D, Cao H, Qian L, et al. beta2-AR-induced Her2 transactivation mediated by Erbin confers protection from apoptosis in cardiomyocytes. Int J Cardiol. 2013;167(4):1570-7.
19. Stern HM. Improving treatment of HER2-positive cancers: opportunities and challenges. Sci Transl Med. 2012;4(127):127rv122.
20. Bhola NE, Grandis JR. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci. 2008;13:1857-65.
21. Arora P, Cuevas BD, Russo A, Johnson GL, Trejo J. Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Oncogene. 2008;27(32):4434-45.
22. Garcia-Recio S, Fuster G, Fernandez-Nogueira P, Pastor-Arroyo EM, Park SY, Mayordomo C, et al. Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer. Cancer Res. 2013;73(21):6424-34.
23. Tang J, Li Z, Lu L, Cho CH. beta-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin Cancer Biol. 2013;23(6 Pt B):533-42.
24. Flierl MA, Rittirsch D, Nadeau BA, Chen AJ, Sarma JV, Zetoune FS, et al. Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature. 2007;449(7163):721-5.
25. Nguyen KD, Qiu Y, Cui X, Goh YP, Mwangi J, David T, et al. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature. 2011;480(7375):104-8.
26. Nandy A, Gangopadhyay S, Mukhopadhyay A. Individualizing breast cancer treatment-The dawn of personalized medicine. Exp Cell Res. 2014;320(1):1-11.
27. Wenjuan Y, Yujun L, Ceng Y. Association of single nucleotide polymorphisms of beta2-adrenergic receptor gene with clinicopathological features of pancreatic carcinoma. Acta Histochem. 2013;115(3):198-203.
28. Chen D, Xing W, Hong J, Wang M, Huang Y, Zhu C, et al. The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection. Ann Surg Oncol. 2012;19(11):3556-65.
29. Bravo-Calderon DM, Oliveira DT, Marana AN, Nonogaki S, Carvalho AL, Kowalski LP. Prognostic significance of beta-2 adrenergic receptor in oral squamous cell carcinoma. Cancer Biomark. 2011;10(1):51-9.
30. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39-51.
31. Vu T, Sliwkowski MX, Claret FX. Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta. 2014;1846(2):353-65.
32. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol. 2011;29(19):2635-44.
33. Ganz PA, Cole SW. Expanding our therapeutic options: Beta blockers for breast cancer? J Clin Oncol. 2011;29(19):2612-6.
34. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(19):2645-52.
35. Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010;1(7):628-38.